Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Norbert Gattermann

Showing results (51-60 of 158) with videos related to

Pageof 16
Sort By:
Leukemia Research|August 22, 2015
Updated recommendations on the management of gastrointestinal disturbances during iron chelation therapy with Deferasirox in transfusion dependent patients with myelodysplastic syndrome - Emphasis on optimized dosing schedules and new formulationsFlorian Nolte, Emanuele Angelucci, Massimo Breccia, et al.
Leukemia Research|June 29, 2011
Incidence and prevalence of myelodysplastic syndromes: data from the Düsseldorf MDS-registryJudith Neukirchen, Wilma M Schoonen, Corinna Strupp, et al.
European Journal of Haematology|May 20, 2018
Effect of deferasirox + erythropoietin vs erythropoietin on erythroid response in Low/Int-1-risk MDS patients: Results of the phase II KALLISTO trialNorbert Gattermann, Rosa Coll, Lutz Jacobasch, et al.
Leukemia Research|February 3, 2009
Impact on survival of different treatments for myelodysplastic syndromes (MDS)Kathrin Nachtkamp, Andrea Kündgen, Corinna Strupp, et al.
Blood|January 25, 2007
High frequency of the JAK2 V617F mutation in patients with thrombocytosis (platelet count>600x109/L) and ringed sideroblasts more than 15% considered as MDS/MPD, unclassifiableNorbert Gattermann, Johan Billiet, Ralf Kronenwett, et al.
Leukemia Research|May 9, 2012
Improved survival in MDS patients receiving iron chelation therapy - a matched pair analysis of 188 patients from the Düsseldorf MDS registryJudith Neukirchen, Frank Fox, Andrea Kündgen, et al.
Haematologica|April 2, 2009
The hematopoietic stem cell transplantation comorbidity index is of prognostic relevance for patients with myelodysplastic syndromeEsther Zipperer, Daniela Pelz, Kathrin Nachtkamp, et al.
Blood|May 25, 2004
Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans retinoic acidAndrea Kuendgen, Corinna Strupp, Manuel Aivado, et al.
International Journal of Laboratory Hematology|January 29, 2024
Validation of a novel algorithm with a high specificity in ruling out MDSFelicitas Schulz, Kathrin Nachtkamp, Howard S Oster, et al.
Annals of Hematology|July 12, 2013
Serum hepcidin measured with an improved ELISA correlates with parameters of iron metabolism in patients with myelodysplastic syndromeEsther Zipperer, Jochen G Post, Matthias Herkert, et al.
Pageof 16

Showing results (51-60 of 158) with videos related to

Sort By:
Pageof 16
Leukemia Research|August 22, 2015
Updated recommendations on the management of gastrointestinal disturbances during iron chelation therapy with Deferasirox in transfusion dependent patients with myelodysplastic syndrome - Emphasis on optimized dosing schedules and new formulationsFlorian Nolte, Emanuele Angelucci, Massimo Breccia, et al.
Leukemia Research|June 29, 2011
Incidence and prevalence of myelodysplastic syndromes: data from the Düsseldorf MDS-registryJudith Neukirchen, Wilma M Schoonen, Corinna Strupp, et al.
European Journal of Haematology|May 20, 2018
Effect of deferasirox + erythropoietin vs erythropoietin on erythroid response in Low/Int-1-risk MDS patients: Results of the phase II KALLISTO trialNorbert Gattermann, Rosa Coll, Lutz Jacobasch, et al.
Leukemia Research|February 3, 2009
Impact on survival of different treatments for myelodysplastic syndromes (MDS)Kathrin Nachtkamp, Andrea Kündgen, Corinna Strupp, et al.
Blood|January 25, 2007
High frequency of the JAK2 V617F mutation in patients with thrombocytosis (platelet count>600x109/L) and ringed sideroblasts more than 15% considered as MDS/MPD, unclassifiableNorbert Gattermann, Johan Billiet, Ralf Kronenwett, et al.
Leukemia Research|May 9, 2012
Improved survival in MDS patients receiving iron chelation therapy - a matched pair analysis of 188 patients from the Düsseldorf MDS registryJudith Neukirchen, Frank Fox, Andrea Kündgen, et al.
Haematologica|April 2, 2009
The hematopoietic stem cell transplantation comorbidity index is of prognostic relevance for patients with myelodysplastic syndromeEsther Zipperer, Daniela Pelz, Kathrin Nachtkamp, et al.
Blood|May 25, 2004
Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans retinoic acidAndrea Kuendgen, Corinna Strupp, Manuel Aivado, et al.
International Journal of Laboratory Hematology|January 29, 2024
Validation of a novel algorithm with a high specificity in ruling out MDSFelicitas Schulz, Kathrin Nachtkamp, Howard S Oster, et al.
Annals of Hematology|July 12, 2013
Serum hepcidin measured with an improved ELISA correlates with parameters of iron metabolism in patients with myelodysplastic syndromeEsther Zipperer, Jochen G Post, Matthias Herkert, et al.
Pageof 16